Peer-reviewed publication in Pattern Recognition demonstrates superiority of VisionGate’s Cell-CT™ patented 3D cell imaging platform



Seattle, WA, September 29, 2008 – VisionGate, a privately held biomed/biotech company, today announced the publisher’s notification of acceptance of a study comparing classification efficacy based on 3D images of cells compared to conventional 2D microscopy of the same cells.

VisionGate’s study, authored by Michael G. Meyer, et al., and entitled “Automated cell analysis in 2D and 3D: A comparative study” is scheduled for publication in early 2009 in Volume 42 (pages 141-146) of Pattern Recognition, the prestigious journal devoted to leading research in pattern recognition, published by Elsevier. The journal article is now available online at: http://dx.doi.org/10.1016/j.patcog.2008.06.018.

VisionGate has demonstrated that 3D imaging of cells is inherently more information rich than the 2D microscope counterpart, and this advantage significantly improves the performance of automated cell disease-state recognition. The publication provides experimental proof of the important advantage of 3D imaging of cells in a study involving the computerized classification of lung adenocarcinoma cell nuclei vs. normal lung  cell nuclei. Particular care was taken to perform 3D and 2D classification on the exact same set of cells, thus avoiding potential sources of bias that might otherwise confound the comparison of 3D and 2D cell imaging. The advantage of 3D over 2D is shown to be statistically significant and increases as higher levels of sensitivity and specificity are demanded.

Dr. Alan Nelson, VisionGate’s Chairman and CEO said: “We have developed a breakthrough technology, called Cell-CT, to automatically interrogate biological cells in their more natural 3D intact condition and measure their internal biomarker features that may be predictive of disease. As we look first to evaluate cell markers for evidence of lung cancer risk, it is important to establish that the Cell-CT platform, with its high-resolution 3D imaging capability, will provide a quantitative advantage over conventional 2D microscopy. This new publication in Pattern Recognition helps establish the important role of 3D cell biomarker analysis in cancer research.”

About VisionGate, Inc.

VisionGate, a privately held corporation in Washington State, has developed an innovative 3D cell imaging and characterization platform,  the Cell-CT, based on the company’s broadly patented technology. The Cell-CT is capable of generating high resolution 3D information from intact cells for automated analysis of cancer biomarkers. Cells are injected into capillary tubes that rotate, allowing multiple viewing angles to tomographically compute the cell’s internal 3D structure; thus enabling spatially defined densitometry of labeled molecular species.


This website may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and made in reliance on the "safe harbor" provisions of said act. Forward-looking statements are based on estimates, projections, beliefs and assumptions of VisionGate® management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. Forward-looking statements are subject to change without notice.

Contact Us

If you are interested in learning more about VisionGate and would like to speak with someone, please complete this short inquiry form and a representative will contact you as soon as possible.


Copyright 2017 - VisionGate, Inc.